Article
Oncology
Rachel Murphy-Banks, Anita J. Kumar, Mingqian Lin, Nicole Savidge, Emma Livne, Susan K. Parsons
Summary: The study explored survivor perceptions of their role in treatment decision-making and understanding of treatment-related late effects (LEs) during active survivorship care. Findings indicated that survivors' role in initial treatment decision-making varied between passive and active, with some expressing unmet information needs. The majority expressed a desire to have learned about LEs before initial treatment ended.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Behavioral Sciences
Tyler C. Alexander, Kevin R. Krull
Summary: Survival rates of childhood acute lymphoblastic leukemia have improved greatly due to advanced therapies, but chemotherapy may lead to neurologic and cognitive problems. Long-term cognitive outcomes remain unclear, but further research is needed to understand the effects of chemotherapy on cognitive function.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2021)
Article
Oncology
Amber Gibson, Adriana Trabal, David McCall, Sajad Khazal, Laurie Toepfer, Donna H. Bell, Michael Roth, Kris M. Mahadeo, Cesar Nunez, Nicholas J. Short, Courtney DiNardo, Marina Konopleva, Ghayas C. Issa, Farhad Ravandi, Nitin Jain, Gautam Borthakur, Hagop M. Kantarjian, Elias Jabbour, Branko Cuglievan
Summary: This study retrospectively reviewed the safety and efficacy of Venetoclax in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma (LBL). The results showed that Venetoclax is safe and effective to use in pediatric patients with ALL/LBL and should be considered in both the relapsed and upfront settings.
Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Review
Pediatrics
Luke Maese, Rachel E. Rau
Summary: Cure rates for pediatric acute lymphoblastic leukemia (ALL) have significantly improved in the past five decades, largely due to the development and understanding of combination chemotherapy. Asparaginase, a recent addition to ALL chemotherapy, plays a crucial role in therapy by depleting the essential amino acid asparagine. Its unique toxicity profile, including hypersensitivity reactions, and the need for therapeutic drug monitoring have influenced the incorporation of asparaginase into ALL treatment. Despite its long-term use and standard-of-care status, there is still room for further improvement in the utilization of asparaginase therapy.
FRONTIERS IN PEDIATRICS
(2022)
Article
Oncology
Sumit Gupta, Rinku Sutradhar, Priscila Pequeno, Johann K. Hitzler, Ning Liu, Paul C. Nathan
Summary: Children with leukemia and Down syndrome (DS) have a higher risk of acute treatment toxicities and late mortality compared to those without DS. DS survivors experienced inferior overall survival compared to non-DS survivors and DS controls. Chronic morbidities associated with DS were not increased compared to DS controls.
Article
Psychology, Multidisciplinary
Kaja Solland Egset, Siri Weider, Jan Stubberud, Odin Hjemdal, Ellen Ruud, Magnus Aassved Hjort, Mary-Elizabeth Bradley Eilertsen, Anne Mari Sund, Magnhild Eitrem Rokke, Trude Reinfjell
Summary: This study examined the feasibility and effectiveness of cognitive rehabilitation program Goal Management Training (GMT) for survivors of childhood acute lymphoblastic leukemia (ALL). Participants completed GMT and showed improved daily life EF and neurocognitive performance at 6-month follow-up. The results suggest that GMT has a positive impact on improving EF impairments.
FRONTIERS IN PSYCHOLOGY
(2021)
Article
Oncology
Vinod A. Pullarkat, Norman J. Lacayo, Elias Jabbour, Jeffrey E. Rubnitz, Ashish Bajel, Theodore W. Laetsch, Jessica Leonard, Susan Colace, Seong Lin Khaw, Shaun A. Fleming, Ryan J. Mattison, Robin Norris, Joseph T. Opferman, Kathryn G. Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C. Pesko, Yan Sun, Jeremy A. Ross, Deeksha Vishwamitra, Lindsey Rosenwinkel, Su Young Kim, Amanda Jacobson, Charles G. Mullighan, Thomas B. Alexander, Wendy Stock
Summary: In this phase I study, combining venetoclax with low-dose navitoclax and chemotherapy showed good tolerability and promising efficacy in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Responses were observed in patients across histologic and genomic subtypes, even in those who had failed stem cell transplant therapies.
Article
Multidisciplinary Sciences
Deepti Reddi, Brandon W. Seaton, David Woolston, Lauri Aicher, Luke D. Monroe, Zhengwei J. Mao, Jill C. Harrell, Jerald P. Radich, Anjali Advani, Nikolaos Papadantonakis, Cecilia C. S. Yeung
Summary: This study investigated the expression of AKR1C3 in T and B-acute lymphoblastic leukemia/lymphoma patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry staining, and Sigma/Millipore Anti-AKR1C3 antibody showed higher specificity. The expression levels of AKR1C3 were evaluated by immunohistochemistry, Protein Wes, and quantitative RT-PCR. Results showed higher AKR1C3 expression in T-ALL samples compared to B-ALL samples. In cases of relapsed/refractory and/or minimal residual T-ALL, Sigma/Millipore Anti-AKR1C3 antibody can aid in AKR1C3 expression.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Maxime Caru, Caroline Laverdiere, Valerie Lemay, Simon Drouin, Laurence Bertout, Maja Krajinovic, Gregor Andelfinger, Daniel Sinnett, Daniel Curnier
Summary: The study demonstrated that childhood ALL survivors exposed to chemotherapy can achieve a safe maximal CPET without long-term complications. Regression analysis showed a significant association between the cumulative dose of doxorubicin and VO(2)peak.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Christine Moore Smith, Debra L. Friedman
Summary: Since the 1950s, the treatment of Hodgkin lymphoma has been evolving, balancing cure and toxicity. Recent advancements in targeted therapies and immunotherapies are changing the landscape. Collaborations and patient-reported outcomes play important roles in driving scientific progress and improving treatment outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Pratik A. Patel, Nicholas P. DeGroote, Kasey Jackson, Thomas Cash, Sharon M. Castellino, Preeti Jaggi, Adam J. Esbenshade, Tamara P. Miller
Summary: This study aimed to describe the risk of bloodstream infection (BSI) and non-BSI in children undergoing therapy for acute lymphoblastic leukemia/lymphoma (ALL/LLy). The results showed a low BSI rate in pediatric patients with ALL/LLy and fever without severe neutropenia, but one-third of the time, patients had a non-BSI, with upper respiratory infection being the most common. Future research should investigate if empiric antibiotics can be tailored based on the associations identified in this study.
Article
Medicine, General & Internal
Seung Min Hahn, Myeongjee Lee, Aaron Huser, Yeonji Gim, Eun Hwa Kim, Minsoo Kim, Amaal M. Aldosari, Inkyung Jung, Yoon Hae Kwak
Summary: This retrospective cohort study examined the incidence and risk factors of osteonecrosis (ON) in Korean pediatric and young adult patients with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study found that older age, radiotherapy, HSCT, steroid use, and anthracycline use were associated with ON development. Furthermore, age, steroid use, and asparaginase use were identified as factors associated with ON in the multivariate analysis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Randa Tao, Yuji Chen, Seungmin Kim, Krista Ocier, Shane Lloyd, Matthew M. Poppe, Catherine J. Lee, Martha J. Glenn, Ken R. Smith, Alison Fraser, Vikrant Deshmukh, Michael G. Newman, John Snyder, Kerry G. Rowe, David K. Gaffney, Ben Haaland, Mia Hashibe
Summary: This study reveals the long-term mental health outcomes and risk factors for mental health disorders in patients diagnosed with Hodgkin lymphoma (HL). Compared with the general population, these patients have a higher risk of anxiety, depression, substance-related disorders, and suicide/self-harm. Undergoing hematopoietic stem cell transplantation is the main risk factor associated with an increased risk of mental health disorders.